Mepolizumab (Nucala)


 CADTH recommends that Nucala should be reimbursed by public drug plans for the treatment of patients with severe chronic rhinosinusitis nasal polyps (CRSwNP) if certain conditions are met.
 only covered to treat adult CRSwNP who have on both sides nose, already had at least 1 surgery their or cannot this type surgery, and still symptoms despite corticosteroid 3 months. When is first prescribed, physicians must submit a baseline Sino-nasal Outcome Test-22 (SNOT-22) score endoscopy polyp so response can measured.
 in whose responding it prescribed physician expertise managing CRSwNP. The cost lowered cost-effective affordable.